- Eye drops
- Intravenous preparation
Ciprofloxacin Market Size was valued at USD x million in 2022 and is poised to grow at a 6.9% CAGR from 2023 to 2029. Ciprofloxacin is one of the broad-spectrum antibiotics for the drug class quinolone antibiotic. To maintain the antibiotic's effectiveness, the antibiotic Ciprofloxacin is largely employed to stop the growth of bacteriophages that are resistant to it. Only bacterial illnesses are treated with the medication ciprofloxacin; viral infections are not affected by it. The Urinary Tract Infections segment anticipated to grow at significant CAGR over the forecast years owing to Due to differences in anatomy, women are more likely than men to get urinary tract infections. In their lifetimes, many women get urinary tract infections more than once. According to some research, there are 150 million cases of urinary tract infections worldwide. Additionally, about 11% of women see a doctor for treatment of a UTI once a year. Moreover, competitors are focusing on launching and acquisition to maintain growth in the market. For instance, In December 2002 FDA Approves Once-Daily Cipro XR for the Treatment of Uncomplicated Urinary Tract Infections (UTIs). Increase in prevalence of bacterial infection such as (UTI), eye infections, among others is anticipated to create lucrative growth opportunities for the ciprofloxacin market.
Fastest Growing Market
The incidence of kidney infections and eye infections is one of the main factors propelling the Ciprofloxacin market's expansion. due to higher efficacy of Ciprofloxacin in treating the infections associated with the excretory system especially renal and urinary system. In June 2018 the US FDA warned the manufacturers and issued guidelines for the labeling black box warning mentioning safety warnings for the fluoroquinolones category of medicines. Considering the drug's negative effects on tendons and skin in paediatric and geriatric patients. It is projected that there would be a significant increase in demand for ciprofloxacin because of the requirement for broad spectrum antibiotics in the global pharmaceutical market.
2022 is the base year and 2029 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.